ArticleInternational journal of clinical and experimental pathology2017
Advanced oxidation protein products accelerated the bone loss and weakened bone strength in ovariectomised rats.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdvanced oxidation protein products (AOPPs) are prevalent in several kinds of disorders. Previous research revealed that the levels of AOPPs in postmenopausal women were significantly higher than that in premenopausal women. Whether AOPPs have any effect on bone loss remains unclear. Our research analysed the role of AOPPs on the development of osteoporosis in ovariectomised (OVX) rats.
methodsFemale SD rats were divided into five groups (SHAM, OVX+PBS, OVX+RSA (Rat Serum Albumin), OVX+AOPPs, OVX+AOPPs+SOD) and subjected to sham or ovariectomy. PBS, RSA, and AOPPs were injected daily with or without intragastric administration of superoxide dismutase (SOD) after surgery. Every 4 weeks blood and the tibia were harvested from eight rats in each group. The expression of osteocalcin and CTX-I (C-terminal crosslinking telopeptide of type I collagen) in serum was measured by ELISA, and the tibiae were subjected to metaphyseal three-point bending and μCT analysis.
resultsAOPPs increased the serum level of osteocalcin and CTX-I. μCT showed AOPPs decreased bone mass at week 4 and week 8, while significant differences in F
conclusionsAOPPs accelerated the bone loss and weakened bone strength in OVX rats.
Indexed as
Identifiers
31966692PMC6965481W3026897085What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.